IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Studies show that administration of interferon (IFN)-alpha causes a significant increase in depressive symptoms. The enzyme indoleamine 2,3-dioxygenase (IDO), which converts tryptophan (TRP) into kynurenine (KYN) and which is stimulated by proinflammatory cytokines, may be implicated in the development of IFN-alpha-induced depressive symptoms, first by decreasing the TRP availability to the brain and second by the induction of the KYN pathway resulting in the production of neurotoxic metabolites. Sixteen patients with chronic hepatitis C, free of psychiatric disorders and eligible for IFN-alpha treatment, were recruited. Depressive symptoms were measured using the Montgomery Asberg Depression Rating Scale (MADRS). Measurements of TRP, amino acids competing with TRP for entrance through the blood-brain barrier, KYN and kynurenic acid (KA), a neuroprotective metabolite, were performed using high-performance liquid chromatography. All assessments were carried out at baseline and 1, 2, 4, 8, 12 and 24 weeks after treatment was initiated. The MADRS score significantly increased during IFN-alpha treatment as did the KYN/TRP ratio, reflecting IDO activity, and the KYN/KA ratio, reflecting the neurotoxic challenge. The TRP/CAA (competing amino acids) ratio, reflecting TRP availability to the brain, did not significantly change during treatment. Total MADRS score was significantly associated over time with the KYN/KA ratio, but not with the TRP/CAA ratio. Although no support was found that IDO decreases TRP availability to the brain, this study does support a role for IDO activity in the pathophysiology of IFN-alpha-induced depressive symptoms, through its induction of neurotoxic KYN metabolites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cytokine-induced activation of the enzyme, indolamine 2,3 dioxygenase (IDO), which metabolizes tryptophan to kynurenine and quinolinic acid, is believed to contribute to reduced availability of serotonin.16,23,24”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [24]
In the citing paper
“Following IDO activation, both the reduced peripheral availability of tryptophan (putatively leading to reduced serotonin synthesis in the brain) and the production of neurotoxic tryptophan metabolites are considered essential steps in the pathophysiological processes.”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“3-hydroxykynurenine and quinolinic acid are NMDA receptor agonists, potentially neurotoxic and thus potentially contributing to depression”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“which converts tryptophan into kynurenine (KYN), a precursor of 3-hydroxykynurenine, a neurotoxic metabolite, and kynurenic acid, a neuroprotective metabolite”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
In the citing paper
“kynurenic acid is an N-methyl d-aspartate (NMDA) receptor antagonist, and is generally considered neuroprotective”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Wichers et al., 2005
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Sheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Research works printed but not linked: 2
- Maes M, Meltzer H . The serotonin hypothesis of major depression. In: Bloom F, Kupfer D, (eds) Psychopharmacology. Raven Press: New York, 1995 pp 933–944.
- Stockmeier CA, Mahajan G, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al. Neuronal and glial density is increased and neuronal soma size is decreased in the hippocampus in major depressive disorder (MDD). Biol Psychiatry 2003; 53S: 198.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
“It should be noted that in addition to depletion of TRP, the generation of KYN also appears to have important effects on neurotransmitter function and behavior (Wichers et al., 2005).”
BackgroundMaes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
“Based on those results, a shift in the serotonin hypothesis of depression from serotonin depletion to inflammation-induced tryptophan and serotonin depletion with subsequent enhanced neurodegeneration by neurotoxic TRYCATs has been proposed (Wichers and Maes 2004; Wichers et al. 2005, 2007).”
BackgroundSelf-citationPenninx, B. W., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-129 · Cited by 839
“The latter is an endogenous N-methyl-D-aspartate agonist that could perturb neurotransmission along glutamatergic pathways and may lead to hippocampal neuron damage and apoptosis which could contribute to depression symptoms [83].”
BackgroundLeonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Self-citationCytokine, Sickness Behavior, and Depression
Dantzer, R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.002 · Cited by 789
“Another possible mechanism is the production of kynurenine metabolites that act as agonists of the glutamate receptors [85] [86].”
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Liu, S., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 775
“Furthermore, a high ratio of plasma kynurenine and tryptophan in patients undergoing IFN-α therapy has been shown to predict depression severity [42, 46, 47].”
BackgroundThe kynurenine pathway: a finger in every pie
Savitz, J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 756
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
“In patients with chronic hepatitis C, up to 24 weeks of treatment with IFNα increased as expected the kynurenine over tryptophan ratio at the same time as it increased symptoms of depression (Wichers et al 2005).”
BackgroundMaes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Self-citationThe immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.014 · Cited by 663
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways
Maes, M., Berk, M., Goehler, L., Song, C., Anderson, G., Gałecki, P., & Leonard, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-66 · Cited by 629
“Physio-somatic symptoms, including fatigue, increased in the first week of treatment, and predicted cognitive-depressive symptoms some weeks to months later [165].”
BackgroundSelf-citationGlucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
“…antagonist, and is generally considered neuroprotective, whereas 3-hydroxykynurenine and quinolinic acid are NMDA receptor agonists, potentially neurotoxic and thus potentially contributing to depression (Wichers and Maes 2004; Wichers et al., 2005; Müller and Schwarz, 2007 Hashimoto, 2009).”
BackgroundMaes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.014 · Cited by 544
Self-citationZhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
Kynurenine pathway in major depression: Evidence of impaired neuroprotection
Myint, A.-M., Kim, Y. K., Verkerk, R., Scharpé, S., Steinbusch, H., & Leonard, B. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.07.013 · Cited by 527
Self-citationThe association between Diabetes mellitus and Depression.
Bădescu, S., Tataru, C. I., Kobylinska, L., Margarint, E. L. G., Zahiu, D., Am, Z., & Zăgrean, A. (2016) · PubMed Central · Cited by 710
Rudzki, L., Ostrowska, L., Pawlak, D., Małus, A., Pawlak, K., Waszkiewicz, N., & Szulc, A. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.10.010 · Cited by 499
“Moreover, kynurenines are believed to play a significant role in the pathogenesis of major depressive disorder (Schwarcz et al., 2012; Steiner et al., 2011; Wichers et al., 2005).”
BackgroundThe role of inflammation and the gut microbiome in depression and anxiety
Peirce, J. M., & Alviña, K. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24476 · Cited by 466
Neuroinflammation and comorbidity of pain and depression
Walker, A. K., Kavelaars, A., Heijnen, C. J., & Dantzer, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008144 · Cited by 460
“Consistently, plasma kynurenine-to-tryptophan ratios are increased in IFN-a–treated patients, which correlate with inflammatory markers and are predictive of depression severity (Capuron et al., 2002, 2003; Wichers et al., 2005; Raison et al., 2010).”
BackgroundFrenois, F., Moreau, M., O’Connor, J., Lawson, M., Micon, C., Lestage, J., Kelley, K. W., Dantzer, R., & Castanon, N. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.03.005 · Cited by 438
“…to a decrease of the bioavailability of tryptophan for serotonin synthesis (Capuron et al., 2002b; Capuron & Dantzer, 2003; Wichers & Maes, 2004) and the generation of potentially neurotoxic tryptophan metabolites such as 3- hydroxykynurenine and quinolinic acid (Stone, 2001; Wichers et al., 2005).”
BackgroundTreatment-resistant depression and peripheral C-reactive protein.
Chamberlain, S. R., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D. N. C., Drevets, W. C., Cowen, P. J., Harrison, N. A., Pointon, L., Pariante, C. M., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.66 · Cited by 400
“52 53 – 55 These effects of inflammation on serotonin transport and tryptophan metabolism may constitute a mechanism by which peripheral inflammation is associated with lack of therapeutic response to selective serotonin reuptake inhibitors.”
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388
“…to reduced serotonin synthesis in the brain), and the relative balance between QUIN and KYNA, have been proposed to be of significance in depression and neurodegeneration (Maes et al, 2009; McNally et al, 2008; Muller and Schwarz, 2007; Myint and Kim, 2003; Myint et al, 2007; Wichers et al, 2005).”
What has serotonin to do with depression?
Cowen, P. J., & Browning, M. (2015) · World Psychiatry · doi:10.1002/wps.20229 · Cited by 374
“Interestingly, lower plasma levels of tryptophan are one of the few reasonably robust findings in patients with more severe forms of depression (7) and, more recently, have been linked to peripheral inflammation and consequent induction of the tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase (8).”
BackgroundLopresti, A. L., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.017 · Cited by 371
“In a study on people undergoing IFN-α treatment for hepatitis C, kynurenic acid levels were positively associated with an increased risk of the development of depression (Wichers et al., 2005).”
BackgroundTrisomy 21 consistently activates the interferon response
Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., et al. (2016) · eLife · doi:10.7554/elife.16220 · Cited by 362
“…of microglia could lead to neurotoxicity by several mechanisms, including serotonin depletion, generation of reactive oxygen species, and excitatory toxicity, which could potentially be ameliorated with inhibitors of the IDO1 enzyme, a key ISG (Wichers and Maes, 2004; Wichers et al., 2005).”
BackgroundExtrahepatic Morbidity and Mortality of Chronic Hepatitis C
Negro, F., Forton, D., Craxì, A., Sulkowski, M. S., Feld, J. J., & Manns, M. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.035 · Cited by 361
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
“In support of a causal relationship between inflammation and psychiatric symptoms, several studies show that immunotherapy with cytokines in patients induces depressive symptoms approximately 1 month after the beginning of the medication (Raison et al, 2009; Wichers et al, 2005).”
BackgroundInflammation, Depression and Dementia: Are they Connected?
Leonard, B. E. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9385-y · Cited by 342
Tryptophan (Trp) modulates gut homeostasis via aryl hydrocarbon receptor (AhR)
Sun, M., Ma, N., He, T., Johnston, L. J., & Ma, X. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1598334 · Cited by 331
Cytokines and Glucocorticoid Receptor Signaling
Pace, T. W. W., & Miller, A. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04984.x · Cited by 339
(2008) · PubMed · Cited by 325
Self-citationZunszain, P. A., Hepgul, N., & Pariante, C. M. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_211 · Cited by 303
O'Connor, J. C., Lawson, M. A., André, C., Briley, E. M., Szegedi, S. S., Lestage, J., Castanon, N., Herkenham, M., Dantzer, R., & Kelley, K. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802722 · Cited by 295
“Increased IDO activity has been positively correlated with the severity of depressive scores (37, 38), but there are as yet no data demonstrating a role for IDO activation as a casual factor in mediating the depression associated with chronic inflammation.”
BackgroundResultMetabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Kaddurah-Daouk, R., & Krishnan, K. R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.174 · Cited by 293
“Abnormalities in lipids and increased inflammation and immune activation may also contribute to the pathogenesis of mood disorders, in part by modulating the metabolism of NT systems (Wichers et al, 2005).”
BackgroundAnisman, H. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0902 · Cited by 292
Miura, H., Ozaki, N., Sawada, M., Isobe, K., Ohta, T., & Nagatsu, T. (2008) · Stress · doi:10.1080/10253890701754068 · Cited by 282
“Although the activation of the KYN pathway has been reported in depression elicited by IFN-a therapy (Bonaccorso et al. 2002; Capuron et al. 2002, 2003; Wichers et al. 2005), the therapy is not the typical cause of clinical depression.”
BackgroundInfluentialSide Effects of Interferon-α Therapy
Sleijfer, S., Bannink, M., Gool, A. R., Kruit, W. H. J., & Stoter, G. (2005) · Pharmacy World & Science · doi:10.1007/s11096-005-1319-7 · Cited by 276
The Concept of Depression as a Dysfunction of the Immune System
E. Leonard, B. (2010) · Current Immunology Reviews · doi:10.2174/157339510791823835 · Cited by 276
Miller, A. H. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.08.006 · Cited by 261
“…agonist that has been implicated in the neurotoxicity of several inflammatory brain diseases such as Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) Dementia Complex and Alzheimer’s disease (Guillemin et al., 2005a,b; Muller and Schwarz, 2007; Wichers et al., 2005).”
Shelton, R. C., & Miller, A. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.004 · Cited by 261
Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder
Sublette, M. E., Galfalvy, H. C., Fuchs, D., Lapidus, M., Grunebaum, M. F., Oquendo, M. A., John Mann, J., & Postolache, T. T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.002 · Cited by 250
Dehhaghi, M., Kazemi Shariat Panahi, H., & Guillemin, G. J. (2019) · International Journal of Tryptophan Research · doi:10.1177/1178646919852996 · Cited by 245
IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors
Chourbaji, S., Urani, A., Inta, I., Sanchis-Segura, C., Brandwein, C., Zink, M., Schwaninger, M., & Gass, P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.05.001 · Cited by 241
“Moreover, therapeutic application of interferon-a in patients with specific forms of cancer or hepatitis C is also associated with increased levels of IL-6 and can give rise to depressive symptoms (Anisman and Merali, 2003; Musselman et al., 2001; Wichers et al., 2005).”
BackgroundThe psychoneuroimmunology of depression
Leonard, B. E., & Myint, A. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1011 · Cited by 236
Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis
Myint, A.-M., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.008 · Cited by 230
Kynurenines: from the perspective of major psychiatric disorders
Myint, A. M. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08551.x · Cited by 229
Bull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Pathophysiology of anorexia in the cancer cachexia syndrome
Ezeoke, C. C., & Morley, J. E. (2015) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12059 · Cited by 225
“When cancer patients are infused with interferon, there is an increased kyreunine/keurinic acid, which is associated with depression and anorexia.(8) This leads”
BackgroundRéus, G. Z., Jansen, K., Titus, S., Carvalho, A. F., Gabbay, V., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.007 · Cited by 221
“Increases in IL-6, decreases in KYNA, or increases in the KYN/KYNA ratio showed a significant association with the development of depressive symptoms in patients with cytokine therapy induced depression (Wichers et al., 2005).”
BackgroundBosi, A., Banfi, D., Bistoletti, M., Giaroni, C., & Baj, A. (2020) · International Journal of Tryptophan Research · doi:10.1177/1178646920928984 · Cited by 221
Oxenkrug, G. F. (2010) · PubMed · Cited by 261
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
“185,187 EVIDENCE FOR TREATMENT OF DEPRESSION IN HCV.”
Ma, K., Zhang, H., & Baloch, Z. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050733 · Cited by 205
“In contrast, kynurenic acid acts as an antagonist of NMDA receptors and can be considered neuroprotective [101].”
BackgroundBarden, N., Harvey, M., Gagné, B., Shink, E., Tremblay, M., Raymond, C., Labbé, M., Villeneuve, A., Rochette, D., Bordeleau, L., et al. (2006) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30303 · Cited by 202
Addressing the tuberculosis–depression syndemic to end the tuberculosis epidemic
Sweetland, A. C., Kritski, A., Oquendo, M. A., Sublette, M. E., Norcini Pala, A., Silva, L. R. B., Karpati, A., Silva, E. C., Moraes, M. O., Silva, J. R. L. E., et al. (2017) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.16.0584 · Cited by 177
Fujigaki, H., Yamamoto, Y., & Saito, K. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.011 · Cited by 178
“…Savitz et al., 2015a, 2015c, 2015d) (Depression with HCV receiving IFNa therapy) [ KYN/TRP (up-regulation of IDO) Serum (human) (Comai et al., 2011; Wichers et al., 2005) [ KYN/KYNA (up-regulation of IDO and/or downregulation of KAT branch) Serum (human) (Wichers et al., 2005) (Depression with…”
InfluentialParrott, J. M., Redus, L., Santana-Coelho, D., Morales, J., Gao, X., & O'Connor, J. C. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.200 · Cited by 174
The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder
Woelfer, M., Kasties, V., Kahlfuss, S., & Walter, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.034 · Cited by 171
Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
Lanser, L., Kink, P., Egger, E. M., Willenbacher, W., Fuchs, D., Weiss, G., & Kurz, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00249 · Cited by 169
HPA and Immune Axes in Stress: Involvement of the Serotonergic System
Leonard, B. E. (2006) · Neuroimmunomodulation · doi:10.1159/000104854 · Cited by 169
Maes, M., Ruckoanich, P., Chang, Y. S., Mahanonda, N., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.008 · Cited by 169
Self-citationMoreau, M., André, C., O’Connor, J. C., Dumich, S. A., Woods, J. A., Kelley, K. W., Dantzer, R., Lestage, J., & Castanon, N. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.04.001 · Cited by 169
“Concurrently, IDO activation results in an increased production of several neuroactive glutamatergic metabolites (Guillemin et al., 2005), and heightened glutamate receptor activity has been recently evidenced in major depression (Muller and Schwarz, 2007; Wichers et al., 2005).”
BackgroundSong, C., Zhang, X. Y., & Manku, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3569-08.2009 · Cited by 169
“Third, proinflammatory cytokines can activate indoleamine 2,3dioxygenase, which may reduce the availability of the serotonin precursor tryptophan to the brain (Song et al., 1998; Wichers et al., 2005).”
BackgroundMuneer, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.507 · Cited by 159
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice
Ledo, J. H., Azevedo, E. P., Clarke, J. R., Ribeiro, F. C., Figueiredo, C. P., Foguel, D., De Felice, F. G., & Ferreira, S. T. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.168 · Cited by 155
Lanser, L., Fuchs, D., Kurz, K., & Weiß, G. (2021) · Nutrients · doi:10.3390/nu13113732 · Cited by 211
Impact of Microbial Metabolites on Microbiota–Gut–Brain Axis in Inflammatory Bowel Disease
Banfi, D., Moro, E., Bosi, A., Bistoletti, M., Cerantola, S., Crema, F., Maggi, F., Giron, M. C., Giaroni, C., & Baj, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041623 · Cited by 173
“Accordingly, the conversion of TRP into KYN after INF-γ-mediated activation of IDO1 promoted the manifestation of depressive symptoms in chronic hepatitis C patients, free of psychiatric disorders [304], while administration of Bifidobacterium infants ameliorated the depressive behavior in rats subjected to the forced…”
MethodLopresti, A. L., Hood, S. D., & Drummond, P. D. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458732 · Cited by 151
“KYNA levels were also associated with an increased risk of depression in people undergoing IFN-α treatment for hepatitis C virus (Wichers et al., 2005).”
BackgroundSavitz, J., Frank, M. B., Victor, T., Bebak, M., Marino, J. H., Bellgowan, P. S. F., McKinney, B. A., Bodurka, J., Kent Teague, T., & Drevets, W. C. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.10.007 · Cited by 146
Maes, M. H. J., Mihaylova, I., Kubera, M., Uytterhoeven, M., Vrydags, N., & Bosmans, E. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.014 · Cited by 154
“In humans, cytokine-based immunotherapy induces depressive symptoms, which are closely related to the induction of the cytokine network and changes in the metabolism of serotonin (Bonaccorso et al., 2002; Wichers et al., 2005).”
BackgroundSelf-citationInflammation in depression: is adiposity a cause?
C. Shelton, R., & H. Miller, A. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/rshelton · Cited by 141
“For example, KYN is metabolized to kynurenic acid (KYNA), which antagonizes α7 nicotinic acetylcholine receptors32 and can reduce striatal dopamine release (see below)37,38 KYN is also metabolized to quinolinic acid (QUIN); QUIN leads to the generation of toxic lipid peroxides and activates N-methylD-aspartic acid (NM…”
Hunt, C., Macedo e Cordeiro, T., Suchting, R., de Dios, C., Cuellar Leal, V. A., Soares, J. C., Dantzer, R., Teixeira, A. L., & Selvaraj, S. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.08.010 · Cited by 139
“Of these 15 studies, ten IFNαstudies were included in the quantitative meta-analysis (Bannink et al., 2007; Baranyi et al., 2015; Bonaccorso et al., 2002; Capuron et al., 2003; Comai et al., 2011; Frick et al., 2004; Pawlowski et al., 2018; Van Gool et al., 2008; Wichers et al., 2005; Zignego et al., 2007).”
BackgroundResultInfluentialLedo, J. H., Azevedo, E. P., Beckman, D., Ribeiro, F. C., Santos, L. E., Razolli, D. S., Kincheski, G. C., Melo, H. M., Bellio, M., Teixeira, A. L., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1269-16.2016 · Cited by 138
“Previous studies have shown that proinflammatory cytokines alter the metabolism of 5-HT (Tuglu et al., 2003; Wichers et al., 2005; Tyring et al., 2006; Zhu et al., 2006; Dantzer et al., 2008), a neurotransmitter closely associated with depressive behavior (Nestler et al.”
InfluentialTryptophan‐derived serotonin‐kynurenine balance in immune activation and intestinal inflammation
Haq, S., Grondin, J. A., & Khan, W. I. (2021) · The FASEB Journal · doi:10.1096/fj.202100702r · Cited by 155
Inflammation-induced depression: Its pathophysiology and therapeutic implications
Jeon, S. W., & Kim, Y.-K. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.10.016 · Cited by 134
“Hippocampal atrophy, which is frequently observed in depression, may be related to the activation of these QUINs (Wichers and Maes, 2004).”
BackgroundNeuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders
Kim, Y.-K., & Jeon, S. W. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170913110426 · Cited by 131
“Meanwhile, KYNA, which is an NMDA antagonist, protects QUINs by offsetting their excitotoxicity [76].”
BackgroundBDNF Impact on Biological Markers of Depression—Role of Physical Exercise and Training
Murawska‐Ciałowicz, E., Wiatr, M., Ciałowicz, M., de Assis, G. G., Borowicz, W., Rocha‐Rodrigues, S., Paprocka‐Borowicz, M., & Marques, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147553 · Cited by 175
“A significant correlation was found between IDO activity, inflammatory markers and the severity of depression [171].”
BackgroundGold, P. W., Licinio, J., & Pavlatou, M. G. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.167 · Cited by 144
The Role of Tryptophan Catabolism along the Kynurenine Pathway in Acute Ischemic Stroke
Brouns, R., Verkerk, R. M., Aerts, T., Surgeloose, D. D., Wauters, A., Scharpé, S., & Deyn, P. P. D. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0187-2 · Cited by 139
“A growing body of evidence illustrates a pivotal role for the kynurenine (KYN) pathway of tryptophan (TRP) oxidation in many neurodegenerative disorders and psychiatric conditions [2–10].”
InfluentialSelf-citationInflammation‐driven brain and gut barrier dysfunction in stress and mood disorders
Doney, E., Cadoret, A., Dion‐Albert, L., Lebel, M., & Ménard, C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15239 · Cited by 151
Maes, M. H. J., Mihaylova, I., Ruyter, M. D., Kubera, M., & Bosmans, E. (2007) · PubMed · Cited by 141
Self-citationMajer, M., Welberg, L. A. M., Capuron, L., Pagnoni, G., Raison, C. L., & Miller, A. H. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.12.009 · Cited by 124
“…shown to dramatically reduce extracellular DA in the rat striatum (Wu et al., 2007), indicating a neuromodulatory role of KA on DA neurotransmission in addition to the previously proposed neuroprotective actions of this metabolite during cytokine (IFN-alpha) administration (Wichers et al., 2005b).”
BackgroundMethodThe putative neurodegenerative links between depression and Alzheimer's disease
Wuwongse, S., Chang, R. C., & Law, A. C. K. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.005 · Cited by 134
“stimulates hippocampal NMDA-receptors, which could eventually lead to neuronal death (Wichers et al., 2005).”
InfluentialAbsence of IFNγ promotes hippocampal plasticity and enhances cognitive performance
Monteiro, S., Ferreira, F. M., Pinto, V, Roque, S., Morais, M., de Sá-Calçada, D., Mota, C., Correia-Neves, M., & Cerqueira, J. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2015.194 · Cited by 124
Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology
Parrott, J. M., & O’Connor, J. C. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00116 · Cited by 123
“depression Human ↑ Kynurenine/KA ratio (interferon-α treatment, serum) (109)”
BackgroundMüller, N., & Schwarz, M. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-2012-3 · Cited by 140
“A recent study showed that depressive symptoms are related to an increased ratio of KYN/KYNA in depression [115].”
BackgroundKetamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Reinstatler, L., & Youssef, N. A. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0081-0 · Cited by 120
“Strong suggestions as to the causal relationship between inflammation and depression/suicidality has come from studies demonstrating that cytokines [30, 31] and interferon-b [32] induce depression and suicidality.”
BackgroundEffects of inflammation on the kynurenine pathway in schizophrenia—a systematic review
Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119
“depressive patients, the augmented concentration of IFN-α was shown to unbalance neurophysiological mechanisms also in subjects with schizophrenia [62].”
BackgroundA biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase
Davies, Christmas, D., & Potokar, J. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s17573 · Cited by 119
“64,103 During IFN-α treatment, the plasma kynurenine:kynurenic acid ratio is increased and this correlates with depressive symptoms.”
InfluentialLoftis, J. M., Huckans, M. S., Ruimy, S., Hinrichs, D. J., & Hauser, P. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.11.001 · Cited by 127
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116
“Recently, the proposed imbalance in the kynurenine metabolism was proven in the IFN-α treated patients (Wichers et al. 2005) and in medication naïve and medication free depressed patients (Myint et al. 2007a).”
BackgroundHoyo-Becerra, C., Schlaak, J., & Hermann, D. M. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.06.200 · Cited by 131
Metadata
- Authors
- Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M.
- Affiliations
- Maastricht University (NL)
- Maastricht University Medical Centre (NL)
- Ziekenhuis Oost-Limburg (BE)
- University of Antwerp (BE)
- Corresponding author
- Wichers, M C
- Venue
- Molecular Psychiatry
- Published
- 2004-10-19
- Volume
- 10
- Issue
- 6
- Pages
- 538-544
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2078660110
- Cited by
- 445
- References
- 54
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 17 · 2023: 17 · 2022: 15 · 2021: 28 · 2020: 23 · 2019: 17 · 2018: 31 · 2017: 20 · 2016: 30 · 2015: 24 · 2014: 17 · 2013: 26 · 2012: 28
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- indoleamine 2,3-dioxygenase, interferon-alpha, depressive symptoms, tryptophan depletion, kynurenine pathway, kynurenic acid, neurotoxicity, chronic hepatitis C, blood-brain barrier, tryptophan availability, inflammatory cytokines
- MeSH terms
- Adult, Depression, Female, Follow-Up Studies, Humans, Immunotherapy, Kynurenic Acid, Kynurenine, Male, Middle Aged, Psychiatric Status Rating Scales, Tryptophan, Interferon-alpha, Hepatitis C, Chronic, Dioxygenases, Indoleamine-Pyrrole 2,3,-Dioxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.